ArticleEBioMedicine2016
One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.
Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04028882 (Immune Activation as a Cause of Insulin Resistance in Adults Living With HIV-1 on Effective Antiretroviral Therapy), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immune Activation as a Cause of Insulin Resistance in Adults Living With HIV-1 on Effective Antiretroviral Therapy
Who cites it
26 citing papers in PubMed.
- Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens.Frontiers in immunology · 2024Trial
- Accumulation of metabolic multimorbidity and its association with mortality: results from a prospective cohort study among people with HIV in China, 2010-2024.The Lancet regional health. Western Pacific · 2026Article
- Antiviral Drugs in HIV and Cardiovascular Disease: Mechanistic Insights and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Neuroinflammation associated with proviral DNA persists in the brain of virally suppressed people with HIV.Frontiers in immunology · 2025Article
- Low-Level Viremia as an Independent Risk Factor for Metabolic Syndrome in People Living with HIV Receiving Antiretroviral Therapy: A 6-Year Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Studying the Changes in Physical Functioning and Oxidative Stress-Related Molecules in People Living with HIV after Switching from Triple to Dual Therapy.Antioxidants (Basel, Switzerland) · 2024Article
- Immune profiles of pre-frail people living with HIV-1: a prospective longitudinal study.Immunity & ageing : I & A · 2024Article
- Elevated plasma levels of IP-10 and MIG are early predictors of loss of control among elite HIV controllers.Frontiers in immunology · 2024Article
- Unveiling neuroimmunology profile of immunological non-responders in HIV: a multimodal MRI approach.Frontiers in immunology · 2024Article
- Low levels of peripheral blood activated and senescent T cells characterize people with HIV-1-associated neurocognitive disorders.Frontiers in immunology · 2023Article
- Inflammatory Markers after Switching to a Dual Drug Regimen in HIV-Infected Subjects: A Two-Year Follow-Up.Viruses · 2022Article
- Cellular Activation, Differentiation, and Proliferation Influence the Dynamics of Genetically Intact Proviruses Over Time.The Journal of infectious diseases · 2022Article
- Insulin resistance is linked to a specific profile of immune activation in human subjects.Scientific reports · 2021Article
- Switching to a Dual-Drug Regimen in HIV-Infected Patients Could Be Associated With Macrophage Activation?Frontiers in medicine · 2021Article
- Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral Therapy.Frontiers in immunology · 2021Article
- Identification of distinct immune activation profiles in adult humans.Scientific reports · 2020Article
- Mitochondrial Dysfunction and Insulin Resistance in Pubertal Youth Living with Perinatally Acquired HIV.AIDS research and human retroviruses · 2020Article
- Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV.Current HIV/AIDS reports · 2020Review
- High levels of genetically intact HIV in HLA-DR+ memory T cells indicates their value for reservoir studies.AIDS (London, England) · 2020Article
- Good Fences Make Good Neighbors: Human Immunodeficiency Virus and Vascular Disease.Open forum infectious diseases · 2019Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune activation in HIV-1-infected individuals is reduced under antiretroviral therapies, but persists, resulting in various morbidities. To better characterize this phenomenon, using a panel of 68 soluble and cell surface markers, we measured the level of activation in circulating CD4+ and CD8+ T cells, B cells, monocytes, NK cells, polynuclear and endothelial cells as well as of inflammation and fibrinolysis in 120 virologic responders over 45years of age. As compared with age- and sex-matched uninfected individuals, we observed a persistence of activation in all the cell subpopulations analyzed, together with marks of inflammation and fibrinolysis. Two independent hierarchical clustering analyses allowed us to identify five clusters of markers that varied concurrently, and five patient groups, each with the same activation profile. The five groups of patients could be characterized by a marker of CD4+ T cell, CD8+ T cell, NK cell, monocyte activation or of inflammation, respectively. One of these profiles was strongly associated with marks of metabolic syndrome, particularly with hyperinsulinemia (OR 12.17 [95% CI 1.79-82.86], p=0.011). In conclusion, our study unveils biomarkers linked to metabolic syndrome that could be tested as predictive markers, and opens the way to new therapeutic approaches tailored to each patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.